Replies to post #737151 on NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

And yet here you stand at 29 cents almost like none of it is real.   Hmm.  

If this company, under the current structure, ever begins to make actual revenue, you'll likely not hear from me again.  

[Chiugray]

Gary, Exactly and that is why we Retail Longs are here.

What Retail Longs do here on IHub is due diligence to invest and share it with everyone (quality DD thru collaboration and networking). If anything, the most important message is: that is how the real wealth is earned and built. If we are fortunate, we identify asymmetric risk-reward opportunities, and if we are lucky will come across a unicorn company like NWBO.

The easiest way to fail is to lose investing discipline, abandon invested DD, and degen into "it's all a gamble".

IMHO, the giant task for an emerging unicorn company is to get a drug successfully through clinical trials, build manufacturing, and protect it with patents. That is substantially done. From an investment standpoint, DCVax-L and the technology platform is substantially de-risked.

- Successful global Phase 3 clinical trial, documented by JAMA publication co-authored by 73 oncologists globally
- Nature publication documented DCVax combined with adjuvant was “safe and enhance systemic immune response”
- Built-out a low cost, state of the art, live cell manufacturing facility, Sawston UK
- Family of DC patents

[Reefrad]

I agree. They are professionals, probably make a good amount of money doing this louthesome job. We on the other hand are just investors who believe in the company. It's a filthy world out there and these guys are part of it.

[iclight]

We actually understand how to read trial data, and what the FDA expects from P3 data, and how the MHRA is a bit player.

You still don't understand the bare basics to be investing in biotech.

How many times have you discussed your hopes and dreams about this stock with ridiculous SP predictions and years-off approval predictions?